Neither crisaborole nor its 2 main metabolites are expected to cause drug interactions by induction or inhibition of cytochrome P450 (CYP) enzymes based on in vitro and in vivo data (see Pharmacology: Pharmacokinetics under Actions).
One of the 2 metabolites showed moderate inhibition of uridine diphosphate (UDP)-glucuronosyltransferase (UGT) 1A9 and may result in a moderate increase in the concentrations of sensitive UGT1A9 substrates (see Pharmacology: Pharmacokinetics under Actions).